Eyecare giant Alcon has bought a majority stake in cell therapy start-up Aurion Biotech, replacing the company's chief executive, in the culmination of a months-long struggle for control.

TOKYO, April 23, 2025--(BUSINESS WIRE)--Aurion Biotech, a clinical-stage regenerative medicine company whose mission is to restore vision to millions of patients, today announced the appointments ...

Morningstar brands and products Company Portfolio ...

Key leadership appointments to accelerate global clinical development of AURN001, a transformational cell therapy for corneal endothelial disease Aurion Biotech is developing AURN001, an ...

Aurion Biotech, a clinical-stage regenerative medicine company whose mission is to restore vision to millions of patients, today announced the appointments of Edward J. Holland, M.D., as Chief ...

Legend Biotech Corporation Sponsored ADR (LEGN) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). An upward trend in earnings estimates -- one of the most ...

Unlike Trump’s first term, the pharmaceutical industry is in far more peril than it has ever been in, and the biotech industry needs to ask itself an important question: Where does it fit in ...

China’s WuXi AppTec, which a US legislative commission called the “Huawei equivalent for biotechnology”, has reported a surge in US business despite increased scrutiny from Washington ...

The market turbulence unleashed by President Donald Trump’s tariff policies will likely evaporate the trickle of biotech IPOs that were expected in 2025, a capital markets expert has told Fierce.

Jonathan Wosen is STAT’s West Coast biotech & life sciences reporter. You can reach Jonathan on Signal at jwosen.27. PALO ALTO, Calif. — At an annual meeting usually focused on the industry ...

Unity Biotechnology, a Bay Area company that once won high-profile backers and a $700 million valuation for its research into aging, is now laying off every one of its remaining employees.